Legal Issues

Patent dispute over Neupogen settled

Published in Cancer Weekly, September 16th, 2003

Biotechnology rivals Genentech, Inc., and Amgen, Inc., have settled a long-running patent dispute over the technology used to produce one of Amgen's top-selling products.

Genentech sued 7 years ago in U.S. District Court alleging that Amgen had infringed on three of its patents while developing Neupogen, a drug used to fight infections in cancer patients undergoing chemotherapy.

Last year, Neupogen sales brought Amgen $1.3 billion.

Under terms of the settlement announced in August, Amgen agreed to make a one-time payment to Genentech, but the company said it would not license any of Genentech's patents. Financial terms were not...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-09-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry